A5066147070- Cancer Immunotherapy and Biomarkers
- Head and Neck Cancer Studies
- Renal cell carcinoma treatment
- Cancer Genomics and Diagnostics
- Prostate Cancer Treatment and Research
- Hedgehog Signaling Pathway Studies
- Thyroid Cancer Diagnosis and Treatment
- Renal and related cancers
- Ear and Head Tumors
- Immunotherapy and Immune Responses
- Pancreatic and Hepatic Oncology Research
- Cancer and Skin Lesions
- Cancer Risks and Factors
- Salivary Gland Tumors Diagnosis and Treatment
- Bladder and Urothelial Cancer Treatments
- Nonmelanoma Skin Cancer Studies
- Cancer Diagnosis and Treatment
- COVID-19 and healthcare impacts
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
- COVID-19 Clinical Research Studies
- Cancer, Lipids, and Metabolism
- Barrier Structure and Function Studies
- SARS-CoV-2 and COVID-19 Research
- Cell death mechanisms and regulation
Fondazione IRCCS Istituto Nazionale dei Tumori
2020-2024
University of Milan
2021-2022
IFOM
2021
Overexpression of human epidermal growth factor receptor type 2 (HER2) occurs in almost 25-30% androgen (AR)-positive salivary gland carcinomas (SGCs), notably duct carcinoma (SDC) and adenocarcinoma not otherwise specified (NOS). In the last years, several studies have reported clinical benefit HER2 directed therapies this setting. This work aims at describing natural history AR-positive recurrent/metastatic (R/M) SGC patients, based on amplification status.
Basal cell carcinoma (BCC) and cutaneous squamous (cSCC) are the most frequent cancers in humans, with cumulative ultraviolet radiation exposure, aging, immunodepression as main risk factors. In cases, these malignancies arise head neck area, they can be treated locoregional therapies. A minority of cases require systemic therapy. Currently, Sonic Hedgehog inhibitors (i.e., vismodegib sonidegib) have been approved for advanced BCC, while PD-1 checkpoint inhibitor cemiplimab has a first-line...
4571 Background: Metastatic collecting ducts carcinoma (mCDC) is a rare disease with bad prognosis and no standard treatments. Due to its rarity, mCDC biologically poorly characterized under-represented in prospective randomized trials. We recently identified two different molecular subtypes of based on relative expression levels angiogenesis, metabolic immune-related genes. Methods: : This prospective, monocentric, phase II trial evaluated cabozantinib (cabo) 60 mg orally once daily until...
High body mass index (BMI) has been associated with worse clinical outcomes in patients early-stage breast cancer (BC), and its negative effects could be mediated by hyperglycemia/diabetes. However, the prognostic impact of high BMI HER2-positive (HER2+) BC remains controversial.We conducted a retrospective study to investigate baseline or glycemia on relapse-free survival (RFS) overall (OS) surgically resected, stage I-III HER2+ treated standard-of-care, trastuzumab-containing adjuvant...
Background Cabozantinib improves survival in metastatic renal cell carcinoma (mRCC) after prior antiangiogenics. The best treatment at disease progression (PD) is unknown. Being also a AXL/MET inhibitor, involved acquired resistance, we hypothesized prolonged tumor growth control patients continuing cabozantinib despite PD.Research Design and Methods This retrospective multicenter study enrolled receiving the first line between 2014 2020. We compared maintaining PD due to clinical benefit...
Abstract Background NUT carcinoma (NUTc) is a rare and aggressive malignant epithelial tumor characterized by rearrangement of the gene on chromosome 15q14. Methods In this article, we present fifth case worldwide young woman affected NUTc arising from submandibular gland, presenting as rapidly evolving mass. She underwent right scialoadenectomy received initial diagnosis high‐grade mucoepidermoid carcinoma. Due to evidence local recurrence at magnetic resonance imaging 1 month later,...
Background: Neoadjuvant anthracycline-taxane-based chemotherapy (ChT) is a standard of care treatment option for stage II–III breast cancer (BC) patients. However, the optimal duration neoadjuvant ChT has been poorly investigated so far. Material and methods: We retrospectively retrieved clinical data patients with human epidermal growth factor receptor 2-negative (HER2–) BC who were treated between October 2007 January 2018 AT (doxorubicin-paclitaxel) three cycles followed by CMF...
Background Pregnancy-associated cancer (PAC) occurs during pregnancy or within 12 months after the delivery. Head and neck (HNC) is infrequent, therefore diagnosis personalized therapy are intricate. Methods We investigated outcomes of 15 PAC patients (5 salivary, 4 nasopharyngeal, 3 thyroid, 2 oral cavity, one HPV-related carcinoma) diagnosed in period 2005-2019. A literature review on provided. Results Median gestational age at was 28 weeks (range: 16–40 weeks) ten cases, 5 delivery 1...
Introduction: The objective response rate to immunotherapy is limited in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) patients, whose prognosis still dismal. Few prognostic factors are clinically available, mostly related patient or disease characteristics. Gene expression signatures offer better abilities but mainly used research. One such GE model classifies HNSCC into 6 clusters with different prognoses. Claudin-1 (CLDN1), which influences tumor microenvironment...
5052 Background: Enzalutamide is a second-generation androgen receptor inhibitor that showed to prolong survival in different setting of prostate cancer. Visceral metastases, occurring 10–30% mCRPC pts, have been associated with poor outcomes. Given the prognosis, trial investigating hormone therapies often excluded men visceral disease, especially pre-docetaxel setting. To date, there are no prospective studies designed ad hoc test this subgroup pts. Methods: In open label phase II...
Various treatments have been considered as the cornerstone for management of patients with metastatic renal cell carcinoma (mRCC) over past two decades.Currently, immunotherapy is a promising clue in landscape frontline treatment mRCC.Immune checkpoint inhibitors (ICIs), which constitute standard therapy pretreated mRCC patients, are emerging possible earlier treatment's strategy mRCC.Otherwise, antiangiogenetics well established backbone mRCC, and research now focused on development...
e18017 Background: RM HNSCC patients (pts) with combined positive score (CPS) ≥1 benefit from immunotherapy (IO), either alone or chemotherapy (CIO). No survival outcome indicators are available. We aim to characterize a real world cohort of pts treated at tertiary cancer center. Methods: analyzed 37 consecutive IO CIO 2016 2022. divided in responders (R) and non (NR) if they achieved an objective response disease stability/progression as best response. For group comparisons, we considered...